It has been shown that therapeutic agents can sensitize tumor cells to TRAIL-initiated apoptosis through mediating TRAIL receptor expression and function [20], [37], [38], [39], [40], [41], [42]. This evidence concerns the gene TNFSF10 and neoplasm.